---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Manufacturing of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep"
date: 2026-02-05 19:08:44 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-05878
original_published: 2024-03-20 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Manufacturing of Anti-Malaria Monoclonal Antibody L9LS in Transgenic Cows and Sheep

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 20, 2024 00:00 UTC
**Document Number:** 2024-05878

## Summary

The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Taurgen Malaria, Inc. ("Taurgen"), headquartered in Logan, UT. Taurgen Malaria, Inc. is a wholly-owned subsidiary of Taurgen Therapeutics, LLC, which is also headquartered in Logan, UT.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/20/2024-05878/prospective-grant-of-an-exclusive-patent-license-manufacturing-of-anti-malaria-monoclonal-antibody)
- API: https://www.federalregister.gov/api/v1/documents/2024-05878

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
